[1] Muzica CM, Sfarti C, Trifan A, et al.Nonalcoholic fatty liver disease and type 2 diabetes mellitus: A bidirectional relationship.Can J Gastroenterol Hepatol, 2020,2020: 6638306.
[2] Lin S, Huang J, Wang M, et al.Comparison of MAFLD and NAFLD diagnostic criteria in real world.Liver Int, 2020,40(9):2082-2089.
[3] Zhou F, Zhou J,Wang W, et al.Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and Meta-analysis.Hepatology,2019,70(4):1119-1133.
[4] Ong JP, Elariny H, Collantes R, et al.Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients.Obes Surg,2005,15(3):310-315.
[5] Younossi ZM, Golabi P, de Avila L, et al.The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.J Hepatol,2019,71(4):793-801.
[6] Ferreira G, Stuurman AL, Horsmans Y, et al.Hepatitis B virus infection and the risk of liver disease progression in type 2 diabetic patients with potential nonalcoholic fatty liver disease: a retrospective, observational, cohort study in the United Kingdom Clinical Practice Research Datalink.Eur J Gastroenterol Hepatol, 2020,32(1):101-109.
[7] Doycheva I, Zhang T, Amjad W, et al. Diabetes and hepatocellular carcinoma: Incidence trends and impact of liver disease etiology.J Clin Exp Hepatol,2020,10(4):296-303.
[8] Kim H, Lee DS, An TH, et al.Metabolic spectrum of liver failure in type 2 diabetes and obesity: From NAFLD to NASH to HCC.Int J Mol Sci,2021,22(9):324-328.
[9] Kumar V, Xin X, Ma J, et al.Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis.Adv Drug Deliv Rev,2021,176:113888.
[10] Caussy C, Aubin A, Loomba R.Therelationship between type 2 diabetes, NAFLD, and cardiovascular risk.Curr Diab Rep,2021,21(5):15.
[11] Wild SH, Walker JJ, Morling JR, etal.Cardiovascular disease, cancer, and mortality among people with type 2 diabetes and alcoholic or nonalcoholic fatty liver disease hospital admission.Diabetes Care,2018,41(2):341-347.
[12] Zhou YY, Zhou XD, Wu SJ, et al.Synergistic increase incardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis.Eur J Gastroenterol Hepatol,2018,30(6):631-636.
[13] Mantovani A, Pernigo M, Bergamini C, et al.Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease.Metabolism,2015,64(8):879-887.
[14] Bonapace S, Perseghin G, Molon G, et al.Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes.Diabetes Care,2012,35(2):389-395.
[15] Lee H, Kim G, Choi YJ, et al.Association betweennon-alcoholic steatohepatitis and left ventricular diastolic dysfunction in type 2 diabetes mellitus.Diabetes Metab J,2020,44(2):267-276.
[16] Targher G, Mantovani A, Pichiri I, et al.Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes.Clin Sci (Lond),2013,125(6):301-309.
[17] Targher G, Valbusa F, Bonapace S, et al.Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes.Nutr Metab Cardiovasc Dis,2014,24(6):663-669.
[18] Mantovani A, Rigolon R, Pichiri I, et al.Nonalcoholic fatty liver disease is associated with an increased risk of heart block in hospitalized patients with type 2 diabetes mellitus.PLoS One,2017,12(10):e0185459.
[19] Jia G, Di F, Wang Q, et al.Non-alcoholic fatty liver disease is a risk factor for the development of diabetic nephropathy in patients with type 2 diabetes mellitus.PLoS One,2015,10(11):e0142808.
[20] Mantovani A, Zaza G, Byrne CD, et al.Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis.Metabolism,2018,79:64-76.
[21] Mantovani A, Sani E, Fassio A, et al.Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes.Diabetes Metab,2019,45(4):347-355.
[22] Zhu X, Yan H, Chang X, et al.Association between non-alcoholic fatty liver disease-associated hepatic fibrosis and bone mineral density in postmenopausal women with type 2 diabetes or impaired glucose regulation.BMJ Open Diabetes Res Care,2020,8(1):129-132.
[23] Keating SE, Hackett DA, Parker HM, et al.Effect of aerobic exercise training dose on liver fat and visceral adiposity.J Hepatol,2015,63(1):174-182.
[24] Kanwal F, Shubrook JH, Younossi Z, et al.Preparing for the NASH epidemic: A call to action.Obesity (Silver Spring),2021,29(9):1401-1412.
[25] Meroni M, Longo M, Rustichelli A,et al. Nutrition and genetics in NAFLD: The perfect binomium.Int J Mol Sci,2020,21(8):621-625.
[26] Association AD.Introduction: Standards ofmedical care in diabetes-2022.Diabetes Care,2021,45(Suppl 1):S1-S2.
[27] Huang YZ, Yang GY, Wang C, et al. Effectiveness of drug interventions in nonalcoholic fatty liver disease: A network meta-analysis.World J Diabetes,2021,12(9):1576-1586.
[28] Ferguson D, Finck BN.Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus.Nat Rev Endocrinol,2021,17(8):484-495.
[29] Musso G, Cassader M, Rosina F,et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.Diabetologia,2012,55(4):885-904.
[30] Radaelli MG, Martucci F, Perra S, et al.NAFLD/NASH in patients with type 2 diabetes and related treatment options.J Endocrinol Invest,2018,41(5):509-521.
[31] Targher G, Corey KE, Byrne CD,et al. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments.Nat Rev Gastroenterol Hepatol,2021,18(9):599-612.
[32] Kuchay MS, Krishan S, Mishra SK, et al.Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial).Diabetologia,2020,63(11):2434-2445.
[33] Zhang LY, Qu XN, Sun ZY,et al. Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease.Clin Res Hepatol Gastroenterol,2020,44(5):674-680.
[34] Sjöström L, Peltonen M, Jacobson P, et al.Bariatric surgery and long-term cardiovascular events.JAMA,2012,307(1):56-65.
[35] Schmid A, Arians M, Karrasch T, et al.Improvement oftype 2 diabetes mellitus and attenuation of NAFLD are associated with the success of obesity therapy.J Clin Med,2022,11(7):432-437. |
